CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes

International Journal of Cancer. Journal International Du Cancer
Amporn LeecharendkeatChirayu U Auewarakul

Abstract

CCAAT/enhancer binding protein-alpha (CEBPA) belongs to a family of leucine zipper transcription factors necessary for late differentiation events of many cell types. CEBPA gene has recently been recognized as the target of genetic alterations in acute myeloid leukemia (AML). CEBPA mutations and polymorphisms were determined in a large series of Southeast Asian AML (n = 247) using polymerase chain reaction and direct sequencing. Chromosome and FLT3 mutation analyses were also undertaken. Thirty-two distinct types of nucleotide changes (7 known and 25 novel mutations) were identified in 34 cases (13.8%). Three types of polymorphisms were found in 60 cases (24.3%) including a novel nt1401C>T polymorphism. All polymorphisms were located at the C-terminal region whereas the majority of mutations (62.5%) occurred at the N-terminal region. The most common polymorphism was the nt1175_1180dup resulting in the predicted P194_H195 duplication protein in 50 cases. Although CEBPA mutations were predominantly associated with a normal karyotype (76%), 15.7% of patients with an unfavorable risk and 4.3% of patients with a favorable risk also had the mutations. Moreover, CEBPA polymorphisms were similarly found across all cytogenetic risk grou...Continue Reading

References

Jun 18, 2002·Blood Cells, Molecules & Diseases·Ota FuchsTomas Stopka
Sep 20, 2002·Blood·James W VardimanRichard D Brunning
Nov 18, 2003·British Journal of Haematology·Jens TiesmeierWalter Verbeek
Jan 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingKonstanze Döhner
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Nov 25, 2004·Hematology·D Gary GillilandCarolyn A Felix
Jan 28, 2005·Leukemia·H LeroyC Preudhomme
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Liang-In LinHwei-Fang Tien
Mar 5, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marianne BienzThomas Pabst
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan FröhlingRoss L Levine
Dec 2, 2005·Current Opinion in Hematology·Beatrice U Mueller, Thomas Pabst
Apr 1, 2006·European Journal of Haematology·Chirayu U AuewarakulChintana Tocharoentanaphol
Jun 24, 2006·Nature Reviews. Cancer·Silvia GrisendiPier Paolo Pandolfi
Jun 15, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlos ResendeJosé C Machado
Oct 16, 2007·Oncogene·T Pabst, B U Mueller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.